Noble Financial Capital Markets Appoints Healthcare Scientific Advisory Board

Tue Dec 4, 2012 1:47pm EST

* Reuters is not responsible for the content in this press release.

  BOCA RATON, FL, Dec 04 (Marketwire) -- 
Noble Financial Capital Markets (Noble) announced today that it has
established a scientific advisory board (SAB). Jules Musing, a Large
Pharma veteran who will chair the Board, is excited about the
developmental prospects for the SAB. "Establishment of this Board
represents a bold strategic initiative for Noble," said Musing. "Not only
are innovations in the Healthcare sector moving forward at a blistering
speed, the regulatory and scientific process has become exceedingly
complex and it takes this kind of commitment to establish credibility
with the various constituents," he said. 

    According to Noble's President, Nico P. Pronk, the SAB is a logical
extension of the services provided to its investment banking, merchant
banking, and corporate advisory clients. "These are seasoned
professionals with extensive experience in cutting edge academic and
clinical research, as well as Big Pharma business development, licensing,
M&A, IP and R&D pipeline strategy," said Pronk. "We are honored to
partner with them, and believe that their breadth of experience and
network will be of great value to our clients and the Noble healthcare
team."

    Noble's Scientific Board of Advisors is comprised of the following
professionals:

    Kapil Dhingra, M.D. 
 Dr. Kapil Dhingra was formerly Vice President and
the Head of the Oncology Disease Biology Leadership Team with Hoffman-La
Roche. He is an experienced oncologist, drug developer and pharmaceutical
executive with a proven track record in academic research, patient care
and drug development from initiation through phase IV. Prior to joining
the industry, he had a successful academic career at M.D. Anderson Cancer
Center. He has been a member of the Board of Directors of Micromet and
Biovex. Presently, he serves on the Boards of Algeta, Exosome Diagnostics
and YM Biosciences and is an advisor to a number of biotechnology and
pharmaceutical companies.

    Victor Hartmann, M.D.
 Dr. Victor Hartmann was formerly the head of
Corporate and Strategic Development at Vertex Pharmaceuticals (NASDAQ:
VRTX), head of the Business Development and Licensing and head of Global
Project Management at Novartis Pharma AG, head of Clinical Research and
Development at Sandoz Pharmaceutical Corporation and head of Medical
Affairs at Boehringer Ingelheim. Dr. Hartmann is currently a consultant
to biotechnology and pharmaceutical companies advising them on business
development transactions, strategic planning and process reengineering
relevant to establishing alliances.

    Robert Karr, M.D. 
 Dr. Karr formerly served as President of Idera
Pharmaceuticals (NASDAQ: IDRA) and continues to serve on the Board. He
has held progressively senior positions, primarily in strategic roles for
Pfizer and Warner-Lambert. Dr. Karr also served as Associate Clinical
Professor of Medicine at the Washington University School of Medicine.
Since obtaining his M.D. from the University of Texas Medical Branch in
1975, Dr. Karr has extensive experience across the drug discovery and
development process (discovery, pre-clinical, and clinical), as well as
experience in fundraising and partnerships with pharmaceutical companies.

    Michael Keller, J.D.
 Mr. Keller is a partner with the law firm Roetzel &
Andress. Throughout his 20-plus legal career, Mr. Keller has focused on
patent prosecution, counseling and licensing of therapeutic, diagnostic,
pharmaceutical and medical device products. He has negotiated complex
product acquisition agreements with companies such as Bristol Myers
Squibb, Glaxo Wellcome, P&G and Pfizer, and has evaluated more than 600
product acquisition candidates.

    Jules A. Musing, Chairman 
 Mr. Musing is the former Global Head of
Biotechnology Licensing and Business Development and has been responsible
for global Drug Licensing at Johnson & Johnson (NYSE: JNJ). In that
position he negotiated and signed several multi-million dollar deals with
medium and large pharmaceutical and biotechnology companies on a
worldwide basis. He has more than 36 years' experience in the
biotechnology and pharmaceutical industry and has been President and
Managing Director of Johnson & Johnson Companies in the US and Europe,
President of Ares Serono in the US and Executive Vice President for Ares
Serono companies in North and Latin America. Mr. Musing has been on the
Board of Johnson & Johnson Companies in Germany, France, Italy and the
UK, and has been a Member of the Management Board of Ortho Biotech, (a
J&J Biotechnology Company) in the US and Europe. He has been a member of
the Board of several companies and presently serves on the Board of
Delphi Digital, Inc., and is an advisor to a number of biotechnology and
pharmaceutical companies.

    Staf Van Reet, Ph.D.
 Dr. Van Reet is a former executive at Johnson &
Johnson who lead corporate venturing activities in Europe and was a
member of the J&J Pharma Group Operating Committee. He has been
responsible for all worldwide R&D activities of the Janssen Group of
Companies as President of the Janssen Research Foundation and has been
Managing Director of Janssen Pharmaceutica N.V. and Janssen Biotech. Dr.
Van Reet is an accomplished Belgian scientist and businessman, who is
currently the Managing Director of Viziphar Biosciences and on the Boards
of several companies including, Actogenix, Okapi Sciences, Octoplus,
Thrombogenix, Biocartis and Therasolve. 

    Noble Financial Capital Markets, established in 1984, is an equity
research-driven, investment banking / corporate advisory boutique with
concentration in the healthcare, technology, media, telecommunications
and business services sectors.

    
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2171996


Mark Pinvidic
561 994 5742 
mpinvidic@noblefcm.com 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.